Abstract 708P
Background
Next generation sequencing (NGS) has become widely available but molecular profiling guided therapy (MGT) has not been established in the real world due to a lack of available therapies and expertise to interpret and match treatment in Korea.
Methods
Patients with advanced solid tumors without remaining standard treatment were enrolled. Virtual, central molecular tumor boards (cMTB) reviewed patients’ NGS reports and recommended clinical trials or investigational medicinal products (IMPs) as previously described (https://doi.org/10.1016/j.esmoop.2022.100653). Primary variable was to assess the proportion of patients with actionable genomic alterations and patients receiving MGT as MTB recommendations. Other variables were duration of treatment (DoT), overall response rate (ORR), disease control rate (DCR) and safety.
Results
From Feb 2021 to Feb 2022, 198 patients were enrolled. Median time from case submission to MTB discussion was 7 days (range, 2-20) and concordance rate between pre-MTB physicians’ choice and MTB recommendations were 60.1% (119/198). A total of 107 (54.0%) received IMPs based on MTB decision (32, TE; 21, AZ; 14, TP; 13, BE; 8, AP; 6, CA; 5, DT; 4, AL; 3, EL; 1, BV). ORR and DCR were 13.3% (1 CR, 9 PR, 45 SD, and 20 PD), and 73.3%. DoT was 3.6 months (95% CI, 2.8-5.0) and 4 months DoT rate (4MDoTR) was 45.5%. DoT>12 months were observed in 10 (9.3%). TE showed a durable DoT, regardless of ERBB2 amplification and mutation (5.8 and 4.0 months), previous exposure of anti-HER2 targeted agents (4.0(No) vs. 5.4 months (Yes)), and high (6>) vs. low (6<) copy number variation (4.0 and 8.0 months).
Table: 708P
| IMPs | ORR | DCR | 4MDoTR | DoT(months) |
| Alectinib (AL) | 33.3% | 33.3% | 50.0% | 3.4 |
| Alpelisib (AP) | 50.0% | 50.0% | 42.9% | 1.4 |
| Atezolizumab (AZ) | 21.4% | 57.1% | 30.0% | 1.9 |
| Bevacizumab (BV) | 0.0% | 100.0% | 100.0% | 8.3 |
| Bevacizumab + erlotinib (BE) | 9.1% | 54.5% | 33.3% | 3.4 |
| Capecitabine (CA) | 0.0% | 100.0% | 0.0% | 1.6 |
| Dabrafenib + trametinib (DT) | 50.0% | 100.0% | 60.0% | 6.9 |
| Erlotinib (EL) | 0.0% | 100.0% | 66.7% | 6.5 |
| Trastuzumab and pertuzumab (TP) | 0.0% | 100.0% | 57.1% | 4.6 |
| Trastuzumab emtansine (TE) | 8.3% | 75.0% | 56.7% | 4.2 |
| All | 13.3% | 73.3% | 45.5% | 3.6 |
Conclusions
KOSMOS suggested the feasibility of nationwide cMTB guided MGT and also showed modest ORR, and a promising DCR in heavily pre-treated patients. KOSMOS-II (NCT05525858) is currently underway to confirm this in larger number of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Korean Society of Medical Oncology, Korean Cancer Study Group.
Funding
Roche. And this study was supported by the National R&D Program for Cancer Control through the National Cancer Center(NCC) funded by the Ministry of Health&Welfare, Republic of Korea (HA22C0052).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
720TiP - Phase I, open-label, first-in-human (FIH) study of JZP815 in advanced or metastatic solid tumors harboring mitogen-activated protein kinase (MAPK) alterations
Presenter: Abdul-Rafeh Naqash
Session: Poster session 17
722TiP - CLAUDIO-01: A multicentric phase I/II trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care (SoC) in patients with gastric, gastroesophageal junction(GEJ), and pancreatic adenocarcinoma
Presenter: Radka Obermannova
Session: Poster session 17
732P - Efficacy and safety of high-dose chemotherapy as second or subsequent salvage therapy in relapsed or refractory germ cell cancer patients: A multicentric analysis
Presenter: Christoph Seidel
Session: Poster session 17
733P - Testicular cancer: Trends in incidence and demographics from 23,214 cases in California from 2000-2020
Presenter: David Benjamin
Session: Poster session 17
734P - Primary retroperitoneal germ-cell tumours (pR-GCT): Evaluation of treatment outcomes of an international collaboration (PRIMERE study-IGG05)
Presenter: Patrizia Giannatempo
Session: Poster session 17